15.10
-0.12 (-0.79%)
| Previous Close | 15.22 |
| Open | 14.75 |
| Volume | 634,923 |
| Avg. Volume (3M) | 1,228,479 |
| Market Cap | 1,552,929,408 |
| Price / Sales | 15.96 |
| Price / Book | 2.97 |
| 52 Weeks Range | |
| Earnings Date | 8 Apr 2026 |
| Operating Margin (TTM) | -340.67% |
| Diluted EPS (TTM) | -2.60 |
| Quarterly Revenue Growth (YOY) | 11.30% |
| Total Debt/Equity (MRQ) | 5.54% |
| Current Ratio (MRQ) | 6.26 |
| Operating Cash Flow (TTM) | -191.72 M |
| Levered Free Cash Flow (TTM) | -106.56 M |
| Return on Assets (TTM) | -31.08% |
| Return on Equity (TTM) | -64.16% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Nurix Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -2.0 |
| Average | -0.38 |
|
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 1.41% |
| % Held by Institutions | 111.85% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 36.00 (Morgan Stanley, 138.41%) | Buy |
| Median | 31.00 (105.30%) | |
| Low | 26.00 (Needham, 72.19%) | Buy |
| Average | 31.63 (109.47%) | |
| Total | 8 Buy | |
| Avg. Price @ Call | 17.72 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BTIG | 29 Jan 2026 | 30.00 (98.68%) | Buy | 17.59 |
| HC Wainwright & Co. | 29 Jan 2026 | 32.00 (111.92%) | Buy | 17.59 |
| Needham | 29 Jan 2026 | 26.00 (72.19%) | Buy | 17.59 |
| Piper Sandler | 29 Jan 2026 | 35.00 (131.79%) | Buy | 17.59 |
| RBC Capital | 29 Jan 2026 | 30.00 (98.68%) | Buy | 17.59 |
| Stifel | 29 Jan 2026 | 35.00 (131.79%) | Buy | 17.59 |
| Wells Fargo | 29 Jan 2026 | 29.00 (92.05%) | Buy | 17.59 |
| Morgan Stanley | 08 Jan 2026 | 36.00 (138.41%) | Buy | 18.63 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 28 Jan 2026 | Announcement | Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update |
| 14 Jan 2026 | Announcement | Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff |
| 12 Jan 2026 | Announcement | Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |